WallStSmart
HAE

Haemonetics Corporation

NYSE: HAE · HEALTHCARE · MEDICAL DEVICES

$52.67
-5.30% today

Updated 2026-05-06

Market cap
$2.75B
P/E ratio
16.33
P/S ratio
2.09x
EPS (TTM)
$3.63
Dividend yield
52W range
$47 – $87
Volume
0.7M

Haemonetics Corporation (HAE) Earnings

Quarterly earnings history, analyst estimates, and stock price reaction.

EPS beat streak
6 of 8
Last 8 quarters
Avg EPS surprise
+7.4%
Last 4 quarters
Revenue YoY growth
-2.7%
Most recent quarter
EPS YoY growth
+28.4%
Most recent quarter

Earnings surprise history (last 12 quarters)

Beat estimate Missed estimate

Quarterly EPS and revenue trend

Quarterly revenue EPS (diluted)

How the stock reacts to earnings

Avg 1-day reaction
-1.3%
Last 3 reports
Positive reaction rate
33%
1 of 3 quarters
Largest single-day move
+34.8%
2025-11-06
Report dateEPS actualSurpriseClose beforeClose after1-day reaction
2026-02-05$0.95+5.6%$65.95$59.34-10.0%
2025-11-06$1.27+14.4%$50.72$68.36+34.8%
2025-08-07$1.10+7.8%$75.77$53.99-28.7%

Quarterly earnings history

Fiscal quarter endingEPS estimateEPS actualSurpriseRevenueYoY revenue
2025-12-31$0.90$0.95+5.6%$338.97M-2.7%
2025-09-30$1.11$1.27+14.4%$327.31M-5.3%
2025-06-30$1.02$1.10+7.8%$321.39M-4.4%
2025-03-31$1.22$1.24+1.6%$330.60M-3.7%
2024-12-31$0.91$0.74-18.7%$348.54M+3.7%
2024-09-30$0.77$0.66-14.3%$345.51M+8.6%
2024-06-30$1.01$1.02+1.0%$336.17M+8.0%
2024-03-31$0.89$0.90+1.1%$343.29M
2023-12-31$0.94$1.04+10.6%$336.25M
2023-09-30$0.89$0.99+11.2%$318.18M
2023-06-30$0.73$1.05+43.8%$311.33M

Frequently asked questions

Has Haemonetics Corporation beaten earnings estimates?
Haemonetics Corporation has beaten Wall Street EPS estimates in 6 of its last 8 quarterly reports, with an average EPS surprise of +7.4% over the last 4 quarters.
How does HAE stock react to earnings?
HAE stock has moved an average of -1.3% in the trading day following earnings over its last 3 reports, with positive reactions in 33% of those quarters.
What is Haemonetics Corporation's revenue growth rate?
Haemonetics Corporation reported year-over-year revenue growth of -2.7% in its most recent quarter, with EPS growing +28.4% year-over-year.